213 related articles for article (PubMed ID: 25679014)
1. LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated.
Zhou W; Zhang J; Marcus AI
Genes Dis; 2014 Sep; 1(1):64-74. PubMed ID: 25679014
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
3. BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer.
Rodriguez-Nieto S; Sanchez-Cespedes M
Carcinogenesis; 2009 Apr; 30(4):547-54. PubMed ID: 19176640
[TBL] [Abstract][Full Text] [Related]
4. Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose.
Inge LJ; Coon KD; Smith MA; Bremner RM
J Thorac Cardiovasc Surg; 2009 Mar; 137(3):580-6. PubMed ID: 19258070
[TBL] [Abstract][Full Text] [Related]
5. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Han D; Li SJ; Zhu YT; Liu L; Li MX
Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
[TBL] [Abstract][Full Text] [Related]
6. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
7. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
[TBL] [Abstract][Full Text] [Related]
8. LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiation.
Zulato E; Ciccarese F; Agnusdei V; Pinazza M; Nardo G; Iorio E; Curtarello M; Silic-Benussi M; Rossi E; Venturoli C; Panieri E; Santoro MM; Di Paolo V; Quintieri L; Ciminale V; Indraccolo S
Biochem Pharmacol; 2018 Oct; 156():479-490. PubMed ID: 30222967
[TBL] [Abstract][Full Text] [Related]
9. IKK promotes cytokine-induced and cancer-associated AMPK activity and attenuates phenformin-induced cell death in LKB1-deficient cells.
Antonia RJ; Baldwin AS
Sci Signal; 2018 Jul; 11(538):. PubMed ID: 29991651
[TBL] [Abstract][Full Text] [Related]
10. Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status.
Zhang J; Nannapaneni S; Wang D; Liu F; Wang X; Jin R; Liu X; Rahman MA; Peng X; Qian G; Chen ZG; Wong KK; Khuri FR; Zhou W; Shin DM
Oncotarget; 2017 Aug; 8(35):59008-59022. PubMed ID: 28938614
[TBL] [Abstract][Full Text] [Related]
11. LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions.
Liu F; Jin R; Liu X; Huang H; Wilkinson SC; Zhong D; Khuri FR; Fu H; Marcus A; He Y; Zhou W
Oncotarget; 2016 Jan; 7(3):2519-31. PubMed ID: 26506235
[TBL] [Abstract][Full Text] [Related]
12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
13.
Deng J; Peng DH; Fenyo D; Yuan H; Lopez A; Levin DS; Meynardie M; Quinteros M; Ranieri M; Sahu S; Lau SCM; Shum E; Velcheti V; Punekar SR; Rekhtman N; Dowling CM; Weerasekara V; Xue Y; Ji H; Siu Y; Jones D; Hata AN; Shimamura T; Poirier JT; Rudin CM; Hattori T; Koide S; Papagiannakopoulos T; Neel BG; Bardeesy N; Wong KK
bioRxiv; 2023 Apr; ():. PubMed ID: 37131623
[TBL] [Abstract][Full Text] [Related]
14. LKB1: Can We Target an Hidden Target? Focus on NSCLC.
Ndembe G; Intini I; Perin E; Marabese M; Caiola E; Mendogni P; Rosso L; Broggini M; Colombo M
Front Oncol; 2022; 12():889826. PubMed ID: 35646638
[No Abstract] [Full Text] [Related]
15. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR.
Sakamoto K; Göransson O; Hardie DG; Alessi DR
Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E310-7. PubMed ID: 15068958
[TBL] [Abstract][Full Text] [Related]
16. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective.
Ciccarese F; Zulato E; Indraccolo S
Oxid Med Cell Longev; 2019; 2019():8730816. PubMed ID: 31781355
[TBL] [Abstract][Full Text] [Related]
17. The molecular mechanisms that underlie the tumor suppressor function of LKB1.
Fan D; Ma C; Zhang H
Acta Biochim Biophys Sin (Shanghai); 2009 Feb; 41(2):97-107. PubMed ID: 19204826
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the LKB1-AMPK signaling pathway does not contribute to salivary gland tumor development - a short report.
Cidlinsky N; Dogliotti G; Pukrop T; Jung R; Weber F; Krahn MP
Cell Oncol (Dordr); 2016 Aug; 39(4):389-96. PubMed ID: 27480082
[TBL] [Abstract][Full Text] [Related]
19. LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway.
Zhang W; Yin L; Song G; Han X; Yin Z; Luo D
Oncotarget; 2017 Dec; 8(69):113847-113857. PubMed ID: 29371951
[TBL] [Abstract][Full Text] [Related]
20. The tumor suppressor kinase LKB1: lessons from mouse models.
Ollila S; Mäkelä TP
J Mol Cell Biol; 2011 Dec; 3(6):330-40. PubMed ID: 21926085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
